For the astute biotechnology investor, Patrys offers a compelling opportunity. Our Deoxymab platform is a novel antibody exploiting its unique properties: the ability to target DNA processes inside the cell; the ability to cross the blood-rain barrier; and their ability to inhibit NETosis, which is associated with the progression of cancers and many infectious, inflammatory, and autoimmune diseases.
Our shareholders are valued partners in our Company – explore our Investors Centre to learn more, subscribe to our email updates and we’ll keep you updated with our progress as we bring this exciting treatment to life.
